2',3'-O-Isopropylidene uridine (2',3'-O-IPU) is a protected derivative of uridine, a nucleoside found in RNA. It is a valuable synthetic intermediate in the preparation of various modified nucleosides, which are used in the synthesis of therapeutic oligonucleotides. The isopropylidene group protects the 2' and 3' hydroxyl groups of uridine, preventing unwanted reactions at these positions. The synthesis of 2',3'-O-IPU typically involves reacting uridine with acetone in the presence of an acid catalyst. This reaction forms a cyclic ketal, protecting the 2' and 3' hydroxyl groups. The isopropylidene group can be removed under mild acidic conditions, regenerating the free hydroxyl groups. 2',3'-O-IPU has been used as a starting material for the synthesis of various modified nucleosides, such as 5-fluorouridine, 5-iodouridine, and 5-bromouridine. These modified nucleosides have been investigated for their therapeutic potential in treating various diseases, including cancer and viral infections. 2',3'-O-IPU is also an important building block for the synthesis of oligonucleotides, which are short sequences of nucleotides that can be used for various applications, such as gene therapy and diagnostics. The importance of studying 2',3'-O-IPU lies in its utility as a synthetic intermediate in the preparation of various modified nucleosides and oligonucleotides. Understanding the chemistry and reactivity of this compound is crucial for developing new and improved therapeutic agents and diagnostic tools. 2',3'-O-IPU has been used in various research studies investigating the synthesis, properties, and applications of modified nucleosides and oligonucleotides. These studies have led to the development of new therapeutic agents and diagnostic tools that have improved patient outcomes.'
2',3'-O-isopropylidene uridine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 64967 |
CHEMBL ID | 1867890 |
SCHEMBL ID | 562430 |
MeSH ID | M0200684 |
Synonym |
---|
2',3'-isopropylideneuridine |
2',3'-o-isopropylideneuridine, >=99% (hplc) |
1-[(3ar,4r,6r,6ar)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]pyrimidine-2,4-dione |
MLS002279958 |
smr001318095 |
NCGC00247402-01 |
1-[(1r,2r,4r,5r)-4-(hydroxymethyl)-7,7-dimethyl-3,6,8-trioxabicyclo[3.3.0]oct- 2-yl]-1,3-dihydropyrimidine-2,4-dione |
HMS2215O22 |
nsc 520038 |
einecs 206-647-7 |
2',3'-o-isopropylidene uridine |
AKOS015892582 |
SCHEMBL562430 |
AKOS024282528 |
CHEMBL1867890 |
1-((3ar,4r,6r,6ar)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)pyrimidine-2,4(1h,3h)-dione |
GFDUSNQQMOENLR-PEBGCTIMSA-N |
D86096 |
CS-W010029 |
BP-58683 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |